TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02862587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cisplatin：60mg/m2，Gemcitabine：1g/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin：60mg/m2，Gemcitabine：1g/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: precision cells
Description: precision cells DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study: NCT03164694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib was given 850 mg per day orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: pemetrexed (500 mg/m2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: pemetrexed (500 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin (AUC =5)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: carboplatin (AUC =5)
Study: NCT03002220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radium-223
Description: Radium-223 at a dose of 55 kBq
Study: NCT04523675

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Orally in three daily dosages (morning-midday-evening), at 20 mg/kg/day, for seven consecutive days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Orally in three daily dosages (morning-midday-evening), at 20 mg/kg/day, for seven consecutive days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder. Orally in three daily dosages (morning-midday-evening), for seven consecutive days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder. Orally in three daily dosages (morning-midday-evening), for seven consecutive days.
Study: NCT03486860

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parent Psychoeducation
Description: 6-session parent psychoeducation group on child anxiety, following their children's lead, and encouraging approach behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Turtle Program
Description: The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
Study: NCT00128102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 100 mg oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vorinostat-matching placebo oral capsules
Study: NCT02666144

Intervention type: DEVICE
Intervention: Spectralis OCT
Description: Measurement of structural parameters of the optic nerve head (ONH), in particular, the neuroretinal rim of the ONH, and the peripapillary retinal nerve fiber layer.

Intervention type: DEVICE
Intervention: Spectralis OCT
Description: Measurement of structural parameters of the optic nerve head (ONH), in particular, the neuroretinal rim of the ONH, and the peripapillary retinal nerve fiber layer.
Study: NCT02225132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: The precise mechanism by which hydroxyurea produces its cytotoxic and cytoreductive effects is not known. However, various studies support the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein.~The mechanisms by which DROXIA produces its beneficial effects in patients with sickle cell anemia (SCA) are uncertain. Known pharmacologic effects of DROXIA that may contribute to its beneficial effects include increasing hemoglobin F levels in RBCs, decreasing neutrophils, increasing the water content of RBCs, increasing deformability of sickled cells, and altering the adhesion of RBCs to endothelium.
Study: NCT03599258

Intervention type: DEVICE
Group type: OTHER
Intervention: Skylife
Description: Newly FDA approved device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Both devices are considered standard therapy
Study: NCT02084563

Intervention type: DRUG
Group type: OTHER
Intervention: Induction Chemotherapy
Description: Induction chemotherapy for patients with AML eligible for intensive chemotherapy:~* Cytarabine 200 mg/m2 IV continuous infusion days 1-7~* Daunorubicin 90 mg/m2 intravenous piggyback days 1-3

Intervention type: DRUG
Group type: OTHER
Intervention: Consolidation Chemotherapy
Description: Consolidation chemotherapy for patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~-Cytarabine 1.5 g/m2 IV in 3 hours days 1, 3 and 5 for 3 cycles
Study: NCT00975936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK706769
Description: 50µg \[14C\]-GSK706769 containing 250 nCi

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: 200 mg Ketoconazole (Q12)
Study: NCT04655417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Tetradecyl Sulfate
Description: DRUG WILL BE INJECTED TO ALLAPTIENTS ACCORDING TO STANDARD PROTOCOL
Study: NCT02125552

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Description: The ultrasound machine will be used to guide intravenous line placement in patients randomized to the ultrasound guided intravenous line group

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional intravenous access
Description: Placement by experienced nurse using standard IV techniques
Study: NCT02084563

Intervention type: DRUG
Group type: OTHER
Intervention: Autologous Stem Cell Transplantation
Description: Autologous Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~* Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~* Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2

Intervention type: DRUG
Group type: OTHER
Intervention: Allogeneic Stem Cell Transplantation
Description: Allogeneic Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with intermediate-/high-risk AML~Conditioning regimen:~* Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~* Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2 or Fludarabine 40 mg/m2 IV once daily days -7 to -4

Intervention type: DRUG
Group type: OTHER
Intervention: Low Dose Cytarabine
Description: Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~* Cytarabine 60 mg/m2 subcutaneous (SQ) bid days 1-5 (until CR or maximum 4 cycles)~* Cytarabine 40 mg/m2 SQ bid days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)

Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~* Decitabine 20 mg/m2 IV once daily days 1-10 (until CR or maximum 4 cycles)~* Decitabine 20 mg/m2 IV once daily days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)
Study: NCT02371291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Flexibility Training
Description: As in experimental arm description.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: As in experimental arm description.
Study: NCT03171662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of Pediatric Appendicitis Score
Description: Imaging and Histopathological examination for Evaluation of Pediatric Appendicitis Score
Study: NCT02863770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EUS enhanced with contrast to evaluate pancreas
Description: Patients will receive intravenous contrast during EUS to assess whether it increases diagnostic yield of the examination
Study: NCT04284605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise combined with strength training
Description: 30 minute aerobic exercise training with warm-up and cool down followed by 30 minute strength training for specific muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise combined with strength training
Description: 30 minute aerobic exercise training with warm-up and cool down followed by 30 minute strength training for specific muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 60 minute yoga intervention including different asanas, breath control and meditation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 60 minute yoga intervention including different asanas, breath control and meditation
Study: NCT02683551

Intervention type: PROCEDURE
Intervention: Sutureless Thyroidectomy
Description: Thyroidectomy performed with energy based devices and no use of ligation. Used device is not altered for this study. Non of the personnel in the operating room including surgical team knows if the patient was enrolled or not in this study.

Intervention type: PROCEDURE
Intervention: Sutureless Thyroidectomy
Description: Thyroidectomy performed with energy based devices and no use of ligation. Used device is not altered for this study. Non of the personnel in the operating room including surgical team knows if the patient was enrolled or not in this study.
Study: NCT04285398

Intervention type: OTHER
Group type: OTHER
Intervention: Ophthalmic examinations
Description: Slit-lamp examination, IntraOcular Pressure, Visual Acuity, Visual Field, Full-field Stimulus Threshold, Dark adaptometry, Color Vision testing, Optical Coherence Tomography, Fundus AutoFluorescence and Adaptive Optics imaging.

Intervention type: OTHER
Group type: OTHER
Intervention: Ophthalmic examinations
Description: Slit-lamp examination, IntraOcular Pressure, Visual Acuity, Visual Field, Full-field Stimulus Threshold, Dark adaptometry, Color Vision testing, Optical Coherence Tomography, Fundus AutoFluorescence and Adaptive Optics imaging.

Intervention type: OTHER
Group type: OTHER
Intervention: Mobility Test
Description: Functional test to evaluate mobility and postural condition of patients
Study: NCT04143945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (administered by DV3396 pen)
Description: Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (administered by DV3396 pen)
Description: Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (administered by PDS290 pen)
Description: Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (administered by PDS290 pen)
Description: Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
Study: NCT02566044

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW276
Description: 0.3 mg and 1.5 mg strengths
Study: NCT02522559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spice Intervention
Description: Spice Intervention:Novel herb and spice blends will be used in cafeteria recipes.
Study: NCT04245059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-channel Transcranial direct current stimulation
Description: A commercial tDCS device will be use in this study. The device is a wireless multi-channel transcranial direct current stimulator that incorporates an 8-channel headcap for stimulation through gel electrodes or classic sponge electrodes. The device is integrated with a user interface for the configuration and monitoring of the stimulus parameters and a fast multifocal simulation of the tDCS electric field using an advanced brain model
Study: NCT05343260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
Study: NCT04069481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: One-hour class, twice a week. Classes include dance warm up exercises, various dance movements and choreography that include coordinated whole body movements through space synchronized to music.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness meditation and Exercise
Description: One hour class, twice a week. Classes include upper and lower extremity stretching and resistance exercises and mindfulness meditation, that includes body scan technique and breathing exercises.
Study: NCT04411693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone implant
Description: A sustained-release drug delivery system containing 0.7 mg of Dexamethasone. Implant is administered by intravitreal injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: A single dose, 2mg, drug administered by intravitreal injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: A single dose, 2mg, drug administered by intravitreal injection.
Study: NCT01914601

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh-King Vision
Description: laryngoscopy will be performed with the Macintosh followed by the King Vision laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: King Vision-Macintosh
Description: laryngoscopy will be performed with the King Vision followed by the Macintosh laryngoscope.
Study: NCT03140280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freeze-Dried Black Raspberry Powder
Description: 25 gm (2x/day) of freeze-dried black raspberry powder taken orally in 8 ounces of water for 12 weeks. If the patient is tolerating BRBs well and is benefiting from therapy, he or she will continue treatment for a total maximum of 48 weeks.
Study: NCT04734743

Intervention type: OTHER
Group type: OTHER
Intervention: cystic fibrosis
Description: Evaluation of Upper Extremity Muscle Strength and Endurance, functional capacity, Respiratory Function and Quality of Life
Study: NCT02713061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-850
Description: TAK-850 injection
Study: NCT03240705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude journaling
Description: Gratitude journaling 3 times a week during surgical rotation
Study: NCT00902928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: SC injection
Study: NCT00663702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Subcutaneous injection, 125 mg/mL, once weekly, 48 months
Study: NCT03524716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit and Text Messages
Description: Physical activity tracker wristband and daily text messages delivered to the participants' phones.
Study: NCT04316117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV
Study: NCT00626990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: Patients randomized to concomitant temozolomide will receive temozolomide continuously at a daily dose of 75 mg/m² during radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: Patients randomized to concomitant temozolomide will receive temozolomide continuously at a daily dose of 75 mg/m² during radiotherapy.
Study: NCT04316117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT03319498

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peppermint Oil Vapor
Description: 2ml of the oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mineral Oil Vapor
Description: 2ml of the mineral oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum.
Study: NCT01981616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab for intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatitis B vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Oral cholera vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine
Study: NCT01973881

Intervention type: PROCEDURE
Intervention: T1 Weighted MRI (magnetic resonance imaging)
Description: Enrolled subjects will have an MRI scan performed at baseline (within 1 month before beginning therapy), at the time of a scheduled bone marrow biopsy or end of treatment cycle (6 months), and after 12 months.~Please note: Patients in this study will be treated with chemotherapy as determined by the hematologist or the treatment protocol for an independent clinical trial for therapy of myelofibrosis. Treatment and monitoring will be performed under the usual standard of care that includes physical examinations, laboratory testing, and other indicated imaging examinations.
Study: NCT00525837

Intervention type: DRUG
Group type: OTHER
Intervention: fixed dose varenicline
Description: varenicline 0.5 mg po daily for days 1-3, 0.5 twice daily for days 4-7, 1 mg twice daily thereafter for study duration.

Intervention type: DRUG
Group type: OTHER
Intervention: varenicline
Description: up to 1 mg twice daily
Study: NCT02655003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIME

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education-only intervention
Description: The staff and physicians in the control nursing homes will receive a 2 hours education session about dementia and neuropsychiatric symptoms
Study: NCT01208285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: 150 mg oral tablet
Study: NCT00626990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: Patients randomized to concomitant temozolomide will receive temozolomide continuously at a daily dose of 75 mg/m² during radiotherapy.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: DNA methylation analysis
Description: O6-Methylguanine-DNA Methyltransferase (MGMT) methylation status is used for stratification at randomization.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: DNA methylation analysis
Description: O6-Methylguanine-DNA Methyltransferase (MGMT) methylation status is used for stratification at randomization.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: DNA methylation analysis
Description: O6-Methylguanine-DNA Methyltransferase (MGMT) methylation status is used for stratification at randomization.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: DNA methylation analysis
Description: O6-Methylguanine-DNA Methyltransferase (MGMT) methylation status is used for stratification at randomization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Prognostic factor analyses

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Prognostic factor analyses